A Study of 2 Doses of MAP0010 in Asthmatic Children

Study Identifier
MAP0010-CL-P301X
CT.gov Identifier
NCT00697697
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Other
Sign up for trial alerts

Study Details

Medical Condition
  • Asthma
    • Study Drug
  • 0.135mg MAP0010
  • 0.25mg MAP0010
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    12 Months - 8 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Completed 12 weeks of treatment in the MAP0010-CL-P301 study. * Patient, parent, and guardian (as appropriate) are willing for child to undergo all study procedures and willing to sign the informed consent and assent, as appropriate.
    Exclusion Criteria:
    * Less than 80% compliance with either study treatment and/or other study procedures (e.g., completion of symptom e-diary) in the MAP0010-CL-P301 Study.

    Protocol Summary

    The purpose of this study is to examine the safety of two doses of MAP0010 in asthmatic children, 12 months to 8 years of age, over a 40-week period.

    Study Locations

    No locations found.